Evaluation of the performance of the model including age at recruitment, sex and smoking status (red) and a classifier including 24-miRNA panel, age at recruitment, sex and smoking status (blue) assessed using the area under Receiver Operating Characteristics (ROC) curves (AUCs) in the IARC case-control study (2006–2012).

<p>Evaluation of the performance of the model including age at recruitment, sex and smoking status (red) and a classifier including 24-miRNA panel, age at recruitment, sex and smoking status (blue) assessed using the area under Receiver Operating Characteristics (ROC) curves (AUCs) in the IARC case-control study (2006–2012).</p

Select baseline characteristics of the study population (lung cancer cases and controls) recruited in the IARC case-control study (Moscow, Russia, 2006–2012).

<p>^a p value calculated using χ² test for categorical variables and Student’s t-test for continuous variables.</p><p>Select baseline characteristics of the study population (lung cancer cases and controls) recruited in the IARC case-control study (Moscow, Russia, 2006–2012).</p

Logistic regression prediction model with the 24-microRNA panel for patients with lung cancer vs controls in the IARC case-control study (Moscow, Russia, 2006–2012).

<p>^a Model containing the 24-miRNA panel (continuous, normalized Ct values).</p><p>^b Model containing sex (Male, Female), age at interview (continuous), smoking status (Never, Former, Current) and the 24-miRNA panel (continuous, normalized Ct values).</p><p>Abbreviations: OR, odds ratio; CI, confidence interval.</p><p>Logistic regression prediction model with the 24-microRNA panel for patients with lung cancer vs controls in the IARC case-control study (Moscow, Russia, 2006–2012).</p

Evaluation of the performance of the 24-miRNA classifier (left) and a classifier including the 24-miRNA panel, age at recruitment, sex and smoking status (right) assessed using area under Receiver Operating Characteristics (ROC) curves (AUCs) in the IARC case-control study (2006–2012).

<p>Evaluation of the performance of the 24-miRNA classifier (left) and a classifier including the 24-miRNA panel, age at recruitment, sex and smoking status (right) assessed using area under Receiver Operating Characteristics (ROC) curves (AUCs) in the IARC case-control study (2006–2012).</p

Complete list of significant differentially expressed miRNA (p-value < 0.05) in lung cancer patients as compared with controls in the IARC case-control study (Moscow, Russia, 2006–2012)—global miRNA expression profiling using TaqMan Human MicroRNA Array A + B Card Set (v3.0).

<p>^a Limma analysis non-adjusted p-value.</p><p>^b p-value corrected for multiple testing (Benjamini-Holm method).</p><p>FC: fold change (> 1 increased; < 1 decreased expression in lung cancer patients vs. non-cancer controls).</p><p>Complete list of significant differentially expressed miRNA (p-value < 0.05) in lung cancer patients as compared with controls in the IARC case-control study (Moscow, Russia, 2006–2012)—global miRNA expression profiling using TaqMan Human MicroRNA Array A + B Card Set (v3.0).</p

MiRNA detected in plasma samples of 100 patients with lung cancer vs 100 controls on TaqMan microRNA CARD A and CARD B, respectively in the IARC case-control study (2006–2012).

<p>MiRNA detected in plasma samples of 100 patients with lung cancer vs 100 controls on TaqMan microRNA CARD A and CARD B, respectively in the IARC case-control study (2006–2012).</p

Hazard ratios (HR) and 95% confidence intervals (CI) for a doubling in vitamin B6 concentration by potential effect modifiers.

<p>Estimates derived from Cox models stratified by country of recruitment, and adjusted for stage, age at recruitment, and sex. <i>p</i>-values are from Wald tests of the interaction terms. A separate estimate for Romania is not provided due to an insufficient number of observations.</p

Model based survival function by categories of circulating vitamin B6 and stage.

<p>Estimates derived from flexible parametric survival models assuming proportional hazards for B6 categories, no interaction between stage and B6 categories, and a diagnosis age of 60y.</p

<i>VIM</i> methylation in cfDNA.

<p>Cases from France (A) and Thailand (B), in tissue (C) (the arrows show the CpG-site analysed in TCGA data) and in TCGA data (D) (the grey area represents the area analyzed by massively parallel sequencing in this study). CTR: controls, HCC: hepatocellular carcinoma patients and CLD: chronic liver diseases. The error bars represent standard error of mean.</p

<i>FBLN1</i> methylation in cfDNA.

<p>Cases from France (A) and Thailand (B), in tissue (C) (the arrows show the CpG-site analysed in TCGA data) and in TCGA data (D) (the grey area represents the area analyzed by massively parallel sequencing in this study). CTR: controls, HCC: hepatocellular carcinoma patients and CLD: chronic liver diseases. The error bars represent standard error of mean.</p